PRPH, US74345W2070

ProPhase units seek votes after USD 25 million claim: what it means for ProPhase Labs stock

Published on 10/16/2026 at 03:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A judge approved plan voting after a USD 25.00 million claim. ProPhase Labs stock had negative USD 0.08 million operating cash flow in June 2026.

Claims and cash flow

A New Jersey judge approved plan voting after a USD 25.00 million claim on October 13, 2026.
Operating cash flow was negative USD 0.08 million in the quarter ended June 2026, up 68.4 percent year over year.
ProPhase Labs had a USD 140,162 market capitalization as of October 15, 2026.

PRPH, US74345W2070, Illustration mit AI erstellt.

ProPhase Labs units sought plan votes after a New Jersey judge granted interim approval for a disclosure statement tied to a USD 25.00 million claim on October 13, 2026, according to Law360. The development concerns ProPhase Diagnostics, the company's COVID-19 testing arm, and places the reorganization process at the center of the stock story.

What does the claim change?

The judge's interim approval allows creditors to vote on the Chapter 11 plan, according to Law360. The USD 25.00 million claim therefore marks a defined legal and financial issue rather than a routine operating update. ProPhase's investor-relations page describes the wider group as a biotech, genomics and consumer-products company with diagnostic services and over-the-counter products.

Cash flow stayed negative

For the quarter ended June 2026, operating cash flow was negative USD 0.08 million and free cash flow was also negative USD 0.08 million, according to Business Quant. The source reports that operating cash flow increased 68.4 percent year over year, but the negative dollar amount still points to continuing cash consumption during the latest reported quarter. The company lists the second quarter of 2026 as its latest financial-results period on its investor-relations page.

Business mix remains broad

ProPhase Labs says its activities include whole-genome sequencing, diagnostic development, contract manufacturing and consumer health products. That mix gives the company several operating lines, while the latest legal process and negative cash flow keep execution and liquidity central to the investor narrative.

Market value and listing

ProPhase Labs had a market capitalization of USD 140,162 as of October 15, 2026. The company identifies Nasdaq as its listing venue for ticker PRPH, while its investor-relations materials also describe the shares as OTC Pink Limited.